Global Therapeutic BCG Vaccines Market Report 2026: Outlook on Opportunities & Challenges
The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.
How Is the Therapeutic BCG Vaccines Market Expected to Expand in Terms of Size and Growth?
The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $59.09 billion in 2025 to $62.77 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to high tb prevalence, rising research in immunotherapy, limited vaccination coverage, government health initiatives, awareness of bcg benefits.
The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $80.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for personalized vaccines, technological advancements in vaccine delivery, rising focus on immuno-oncology applications, expansion of public health programs, growing investment in biotech innovations. Major trends in the forecast period include personalized bcg therapy development, vaccine delivery innovations, expanded research in tb immunotherapy, combination therapies with bcg, government-funded immunization programs.
Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Which Factors Are Driving Growth in the Therapeutic BCG Vaccines Market?
The rising number of tuberculosis (TB) cases worldwide will propel the growth of the therapeutic BCG vaccine market going forward. Tuberculosis (TB) is an infectious illness that can be potentially dangerous and primarily impacts the lungs. People can contract tuberculosis from one another by coughing or sneezing small droplets of bacteria into the air. BCG vaccines are used to stimulate the immune system to fight infection but do not cause TB since the germs are weak. It consistently offers protection against the most dangerous types of TB, such as adolescent TB meningitis. The BCG vaccine protects against tuberculosis which helps to fight against infection, hence the usage of therapeutic BCG vaccines increased. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Therefore, the rising number of tuberculosis (TB) cases worldwide is driving the growth of the therapeutic BCG vaccine market.
What Segment Defines the Therapeutic BCG Vaccines Market?
The therapeutic bcg vaccines market covered in this report is segmented –
1) By Type: Therapy BCG, Other Types
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users
What Are the Key Trends Shaping the Therapeutic BCG Vaccines Market?
Major companies operating in the therapeutic BCG vaccine market are focused on innovating vaccines for potential therapeutic applications in various medical conditions, such as BCG immunotherapy, to expand their customer base and meet growing patient needs. BCG (Bacillus Calmette-Guérin) immunotherapy refers to the use of the BCG vaccine as a form of immunotherapy to treat certain types of cancer, particularly bladder cancer. For instance, in July 2023, The Serum Institute of India, an India-based biotechnology and biopharmaceuticals company, received government approval to export its BCG vaccine to Canada for immunotherapeutic use in treating bladder cancer. This live freeze-dried preparation, derived from an attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin), is intended for intravenous instillation. The vaccine is available in 40 mg and 80 mg presentations. As an integral part of the therapy, the vaccine is administered directly into the bladder through a catheter, where it remains in the bladder lining for a specified duration. This targeted approach aims to impact cancer cells effectively while minimizing impact on other parts of the body.
Who Are the Prominent Players in theTherapeutic BCG Vaccines Market?
Major companies operating in the therapeutic bcg vaccines market are Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, Bharat Biotech International Ltd., Shanghai Institute of Biological Products Co. Ltd., Instituto Butantan, BioCen, Panacea Biotec Ltd., Institute Pasteur de Tunis, Korean BCG Vaccine Institute
Get the full therapeutic bcg vaccines market report here:
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Which Regions Offer the Highest Potential for Therapeutic BCG Vaccines Market Expansion?
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2025. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment